Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

ABSTRACT:

Objectives

Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung cancer (NSCLC) and may differentially influence patient outcomes. We sought to characterize the effects of KRAS mutation subtypes and concurrent pathogenic mutations on overall survival (OS) and PD-L1 expression, a predictive biomarker for anti-PD-1/PD-L1 immunotherapy.

Materials and methods

We retrospectively identified patients with KRAS-mutant NSCLC at a single institution and abstracted clinical, molecular, and pathologic data from electronic health records. Cox regression and multinomial logistic regression were used to determine how KRAS mutation subtypes and concurrent pathogenic mutations are associated with OS and tumor PD-L1 expression, respectively.

Results

A total 186

SUBMITTER: Aredo JV 

PROVIDER: S-EPMC9348589 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature